Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial (Q42477102)

1 November 2017

title

Vismodegib in patients with advanced basal cell carcinoma (STEVIE): a pre-planned interim analysis of an international, open-label trial (English)

1 reference

1 November 2017

3

1 reference

1 November 2017

5

Brigitte Dréno

0 references

Paolo Antonio Ascierto

7

object named as

Paolo A Ascierto

1 reference

1 November 2017

14

Reinhard Dummer

1 reference

1 November 2017

15

Kate Fife

1 reference

1 November 2017

2

Axel Hauschild

1 reference

1 November 2017

Nicole Basset-Seguin

1

1 reference

1 November 2017

Rainer Kunstfeld

4

1 reference

1 November 2017

Brigitte Dréno

5

1 reference

1 November 2017

Laurent Mortier

6

1 reference

1 November 2017

Lisa Licitra

8

1 reference

1 November 2017

Caroline Dutriaux

9

1 reference

1 November 2017

Luc Thomas

10

1 reference

1 November 2017

Thomas Jouary

11

1 reference

1 November 2017

Nicolas Meyer

12

1 reference

1 November 2017

Bernard Guillot

13

1 reference

1 November 2017

D Scott Ernst

16

1 reference

1 November 2017

Sarah Williams

17

1 reference

1 November 2017

Alberto Fittipaldo

18

1 reference

1 November 2017

Ioannis Xynos

19

1 reference

1 November 2017

Johan Hansson

20

1 reference

1 November 2017

publication date

13 May 2015

1 reference

Lancet Oncology Commission

1 November 2017

published in

1 reference

1 November 2017

volume

16

1 reference

1 November 2017

issue

6

1 reference

1 November 2017

page(s)

729-736

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

1 November 2017

1 reference

7 January 2021

Advanced basal cell carcinoma of the skin: targeting the hedgehog pathway

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Basal cell carcinomas in a tertiary referral centre: a systematic analysis.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Challenges and new horizons in the management of advanced basal cell carcinoma: a UK perspective

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Identifying locally advanced basal cell carcinoma eligible for treatment with vismodegib: an expert panel consensus.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Basal cell carcinoma: from the molecular understanding of the pathogenesis to targeted therapy of progressive disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Advanced, neglected basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Basal cell carcinomas: attack of the hedgehog

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

1 reference

7 January 2021

Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Efficacy and safety of vismodegib in advanced basal-cell carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Emerging drugs and combination strategies for basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

A phase I, multicenter, open-label, first-in-human, dose-escalation study of the oral smoothened inhibitor Sonidegib (LDE225) in patients with advanced solid tumors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Treatment with two different doses of sonidegib in patients with locally advanced or metastatic basal cell carcinoma (BOLT): a multicentre, randomised, double-blind phase 2 trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

U.S. Food and Drug Administration approval: vismodegib for recurrent, locally advanced, or metastatic basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Metastatic basal cell carcinoma: prognosis dependent on anatomic site and spread of disease

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

An investigator-initiated open-label clinical trial of vismodegib as a neoadjuvant to surgery for high-risk basal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2815%2970198-1

7 January 2021

10.1016/S1470-2045(15)70198-1

Identifiers

DOI

1 reference

1 November 2017

1 reference